This Resource Centre will retire this year and will not be available after 31 December 2017. Content will remain here for browsing and downloading prior to that date. Thank you for your interest.

The Advances in Gastrointestinal Cancer Resource Centre Introduction

The Advances in Gastrointestinal Cancer Resource Centre is dedicated to disseminating cutting-edge data to practising healthcare professionals. Our aim is to provide clinically relevant information, in order to enhance your ability to provide optimal care for your patients with gastrointestinal (GI) cancer. We offer journal articles, patient case reports, interviews, and roundtable discussions with experts, with additional content aimed at expanding your expertise in the multidisciplinary field of GI cancer. This freely available resource, hosted by European Journal of Cancer and Clinical Colorectal Cancer, functions as an information hub for healthcare professionals

Advances in Gastrointestinal Cancer having focused initially on gastric cancer, has now expanded its scope to include all GI malignancies. New content will be posted monthly, and the Editors encourage you to visit the site regularly to stay abreast of recent scientific developments in the management of GI cancers. Please subscribe to our eAlert to ensure you are informed of all new content as it is published on this platform.

This Resource Centre will retire this year and will not be available after 31 December 2017.
Content will remain here for browsing and downloading prior to that date. Thank you for your interest.

(closes after 5 sec.)

Editorial comment on Cancer Esophagus Gefitinib (COG) study

Commentary by Prof Lordick and Dr Elizabeth Smyth:
Several randomized controlled trials investigating EGFR-directed drugs - monoclonal antibodies and TKI’s - in upper gastrointestinal cancers, including EXPAND, REAL-3 and COG, were published over the last years. All of these were negative for efficacy endpoints and there was only little hope that subgroups of tumours maybe identified which can be treated with EGFR-inhibitors. The preplanned analysis of EGFR-FISH from the COG (Cancer Esophagus Gefitinib) Study indicates such a subgroup of patients who may derive benefit from Gefitinib after failure of previous chemotherapy.

Editorial comment on GATSBY study

Commentary by Prof Lordick and Dr Elizabeth Smyth:
Trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer. Until today, there is no established anti-HER2 therapy in the second-line setting. The Gatsby study (trastuzumab emtansine [TDM-1] versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma) investigated whether the anti-HER2 antibody-drug conjugate TDM-1  at a dose of 2.4mg/m2 weekly leads to better overall survival compared with taxane alone, (Thuss-Patience et al.)

Editorial comment on the AIO-FLOT3 Trial

Commentary by Prof Lordick and Dr Elizabeth Smyth:
FLOT-3 shows there is an intermediate prognostic group of gastric cancer consisting of patients who present with limited metastatic spread to distant lymph nodes or oligotopic distant organ metastases. Patients with these intermediate clinical stages have a worse prognosis than patients with only locoregional disease but they have a better prognosis than patients with multifocal distant spread. Patients with limited metastatic burden could benefit from multimodality treatment including surgery.   What this observation means for clinical decision making in routine practice should be clarified in prospective controlled trials.

Latest Articles

Editor's choice of ASCO GI abstracts

  • Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406)

    Scott Kopetz, Shannon L McDonough, Van Karlyle Morris, Heinz-Josef Lenz, Anthony Martin Magliocco, Chloe Evelyn Atreya, et al.

    J Clin Oncol 35, 2017 (suppl 4S; abstract 520)

    Editorial comment from Prof. Florian Lordick:
    Survival outcomes for patients with BRAF-mutated metastatic colorectal cancers are much worse than for patients with BRAF wildtype tumors. BRAFinhibition alone was not shown to be effective in previous studies. This randomized controlled studyshows that dual inhibition of the EGFR and BRAF dependent pathway by combining cetuximab,vemurafenib in addition to standard chemotherapy with irinotecan is an effective treatment for thismolecular subtype of colorectal cancer. This confirms previous observation from uncontrolled smallertrials and may eventually lead to a new treatment option for patients who failed on previouschemotherapy.

  • Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial

    Julien Edeline, Franck Bonnetain, Jean Marc Phelip, Jérôme Watelet, Pascal Hammel, Jean-Paul Joly et al.

    J Clin Oncol 35, 2017 (suppl 4S; abstract 225)

    Editorial comment from Prof. Florian Lordick: 
    Survival outcomes for patients with resected biliary tract cancers are dismal. This French multicenter study is the first adequately powered prospectiverandomized controlled trial assessing the efficacy of adjuvant chemotherapy in resected biliary tractcancers. Unfortunately, the primary endpoint of this study, an improvement in relapse-free survival, wasnot met. Longer follow-up and survival results should be awaited. Moreover, other studies investgatingother, maybe more adequate treatment regimens than gemcitabine-oxaliplatin, are investigated inother national networks.

  • Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial

    Yoon-Koo Kang, Taroh Satoh, Min-Hee Ryu, Yee Chao, Ken Kato, Hyun Cheol Chung, et al.

    .J Clin Oncol 35, 2017 (suppl 4S; abstract 2)

    Editorial comment from Prof. Florian Lordick: 
    This is the first study that proofs the efficacy of immune checkpoint inhibition in the situation of chemotherapy refractory advanced gastric cancer. It isimportant that part of the patients achieved long duration of response or long duration of stabledisease, which contributes to the overall positive survival results with a considerable number of patientsin the investigational arm who survive for 12 months or longer. It will be important to define biomarkersand other predictors for benefit and longterm survival in order to select the right patients for immunecheckpoint blockade. ONO-4583 did not report such analyses thus far. In addition, we are waiting forresults from studies that investigate immune checkpoint inhibitors in earlier lines of treatment, incombination with chemotherapy and biologics and in the adjuvant setting.

Editor in Chief

Professor Florian Lordick

University Hospital Leipzig, Leipzig, Germany

Advisory Editors

Dr Ian Chau

Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK

Dr Elizabeth Smyth

Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK

Professor Michel Ducreux

Department of Medical Oncology, Gustav Roussy, Paris, France

Dr Chiara Cremolini

Oncology Department, Santa Chiara Hospital, University of Pisa, Pisa, Italy

Former Editors

Professor David Cunningham (Editor in chief 2015 - 2016)

Director of the Royal Marsden/Institute of Cancer Research NIHR Biomedical Research Centre and Director of Clinical Research

Dr James J. Lee (Advisory Editor 2015-2016)

Division of Medical Oncology and Hematology, UPMC Cancer Centre, Pittsburgh, PA, USA

Search this site

Search form

ECCO2017 symposium webcast: Treatment evolution in advanced GI malignancies

Welcome and introduction - Florian Lordick


Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Featured Content

New Book Content

This online Resource Centre has been sponsored by Lilly Oncology

Note that Lilly Oncology has no editorial control over the content of this Resource Centre. The Resource Centre and all content therein has been subject to an independent editorial review.


Upcoming events